Commercial Strategy

We are committed to addressing the global health threat posed by antibiotic-resistant superbugs by pioneering a New Class of Synthetic Anti-Infectives. Our approach to treating bacterial infections has the potential to transform the current anti-infective business model.

Proprietary new class of anti-infectives against bacteria protected by Composition of Matter Patent.

Broad spectrum therapeutic potential for sepsis/urosepsis, burn wound infections, diabetic foot infections and more.

Strong pre-clinical data package demonstrating high bactericidal activity combined with very good safety at expected human therapeutic range.
State of the Art manufacturing capacities ensuring highly attractive manufacturing costs and scalability.
Multiple Phase I and Phase II clinical programs, addressing the needs of the patients battling bacterial infections.